Updated results from the KATHERINE trial showed that adjuvant T-DM1 provided a significant improvement in overall survival and no evidence of long-term safety issues.

Precision medicine is a kind of personalized cancer care treatment where every cancer patient is treated differently.

Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.